“Interactions between genetic and environmental factors are thought to contribute to the pathogenesis of the majority of Parkinson’s disease (PD) cases. However, our understanding of these interactions is at an early stage. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of hereditary PD. Penetrance of LRRK2 mutations is incomplete and variable, suggesting that other environmental or genetic factors may contribute to the development of the disorder. Recently, using animal models, several attempts have been made
to understand if LRRK2 may mediate sensitivity to environmental neurotoxicants. Here, we critically review the most current data on how LRRK2 mutations influence neurotoxicity in PD models.”
“Some children with severe asthma develop frequent exacerbations despite intensive treatment.\n\nWe Pfizer Licensed Compound Library mouse sought to assess the outcome (severe exacerbations and healthcare use, lung function, quality of life and maintenance treatment) of a strategy based on daily home spirometry with teletransmission to an expert medical centre and whether it differs from that of a conventional strategy.\n\n50 children with severe uncontrolled asthma were enrolled in a 12-month prospective study and were randomised https://www.selleckchem.com/products/VX-770.html into two groups: 1) treatment managed with daily home spirometry and medical feedback (HM) and 2) conventional treatment (CT).\n\nThe children’s mean age
was 10.9 yrs (95% confidence interval 10.2-11.6). 44 children completed the study (21 in the HM group and 23 in the CT group). The median number of severe exacerbations per patient was 2.0 (interquartile range 1.0-4.0) in the HM group and 3.0 (1.0-4.0) in the CT group (p=0.38 with adjustment for age). There were no significant differences between the two groups for https://www.selleckchem.com/products/azd5582.html unscheduled
visits (HM 5.0 (3.0-7.0), CT 3.0 (2.0-7.0); p=0.30), lung function (pre-beta(2)-agonist forced expiratory volume in 1 s (FEV1) p=0.13), Paediatric Asthma Quality of Life Questionnaire scores (p=0.61) and median daily dose of inhaled corticosteroids (p=0.86).\n\nA treatment strategy based on daily FEV1 monitoring with medical feedback did not reduce severe asthma exacerbations.”
“A novel beta-glucosidase (BglPm) was identified from Paenibacillus mucilaginosus KCTC 3870(T) which has ginsenoside converting activity. The gene, termed bglPm, consists of 1,260 bp and belongs to glycoside hydrolase family 1 (GH1). After being overexpressed and purified from Escherichia coli, the enzymatic properties of BglPm were investigated. The enzyme exhibited an optimal activity at 45 degrees C and pH 7.5 and showed high bioconversion ability for major ginsenoside Rb-1 and Rd into ginsenoside F-2. Thus, it was used for mass production of relatively high pure F-2 from relatively abundant protopanaxadiol type ginsenosides mixture (PPDGM) with combined usage of ginsenoside Rc-hydrolyzing enzyme.